By Katie Eder
The US Food and Drug Administration (FDA) has approved Xiaflex (collagenase clostridium histolyticum) as the first non-surgical treatment for Peyronie’s disease.
Healthy food/diet patterns cost more, according to a meta-analysis published online Dec. 5 in BMJ Open.
A practical approach may be used to offer mind-body regulation training to medical students, according to research published in the Fall issue of the Annals of Behavioral Science and Medical Education.
Xiaflex (collagenase clostridium histolyticum) has been approved by the U.S. Food and Drug Administration to treat Peyronie's disease. The drug -- first sanctioned three years ago to treat Dupuytren's contracture -- is the first medication to be approved by the agency to treat Peyronie's.
By Jackie Syrop
A new report from the Institute of Medicine (IOM) calls for a national surveillance program that will help create enough data on concussions in young athletes to counter the lack of information on the phenomenon, as well as resist what the agency calls “a culture of resistance” pervading youth sports.
The final hospital outpatient and ambulatory surgical center (ASC) payment rule will give hospitals and ASCs the ability to lower costs, according to a report from the Centers for Medicare & Medicaid Services (CMS).
Serum 25-hydroxyvitamin D seems to be a marker of ill health and not a causal factor, according to a review published online Dec. 6 in The Lancet Diabetes & Endocrinology.
Concerns surround implementation of the Medicare Hospital Readmissions Reduction Program, according to a policy brief published online Nov. 12 in Health Affairs.
For individuals with clinically isolated syndromes, a first demyelinative episode that often precedes multiple sclerosis, Bacille Calmette-Guérin vaccination correlates with reduced development of gadolinium-enhancing lesions, according to a study published online Dec. 4 in Neurology.